Biotech Momentum Continues
Eikon’s market entrance comes amid a flurry of biotech activity. Just one day earlier, hair loss drug developer Veradermics Inc. launched its own public debut after raising $256 million in an upsized offering.
Veradermics sold 15.1 million shares at $17 apiece — above its marketed range of $14 to $16 — after previously announcing plans to offer nearly 13.4 million shares. The company began trading Wednesday on the New York Stock Exchange.
Together, the back-to-back listings signal renewed energy in biotech capital markets, where innovation and investor optimism are once again converging.
With Eikon’s Upsized $381M IPO now etched into Nasdaq’s trading history, the company begins its next chapter — one measured not only in share prices, but in clinical milestones and the promise of new cancer therapies.
